Last updated on July 2019

Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or S zary Syndrome (SS)


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: cutaneous T-cell lymphoma | Sezary Syndrome | Mycosis Fungoides | Szary Syndrome
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Main Inclusion Criteria:

  • Patients with histologically confirmed MF (Stage IIB-IVB) or SS in an ongoing complete response (CR), partial response (PR) or stable disease (SD) after at least one prior systemic therapy according to local standards (including but not limited to -interferon, bexarotene, total skin electron beam irradiation, chemotherapy) [the most recent systemic therapy must have been completed as planned or stopped due to unacceptable toxicity 2-12 weeks prior to randomisation]
  • Eastern Cooperative Oncology Group (ECOG) status score 0-2
  • Adequate haematological, hepatic and renal function

Main Exclusion Criteria:

  • Patients with progressive disease (PD)
  • Baseline corrected QT (QTc) interval > 500 milliseconds
  • Concurrent use of any other specific anti-tumour therapy including psoralen photo chemotherapy (PUVA), chemotherapy, immunotherapy, hormonal therapy, radiation therapy, or experimental medications

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.